US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Research & Development Market Research Reports & Industry Analysis

The term research and development (R&D) refers to work that is done in order to better understand the nature, function or understanding of a topic or product in order to gain knowledge and find new applications for existing products or to develop new and innovative products. This is usually performed by corporations, government agencies, and research or academic institutions.

New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.

Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.

RSS Feeds

Research & Development Industry Research & Market Reports

< prev 1    3  4  5  6  7  8  9  10  
Marijuana Stores
9/5/2016 | published by: First Research, Inc.
... The multi-billion dollar global industry is experiencing strong growth, though the newness of the market and variance in regulation across geographies creates major barriers to entry. The industry includes medical marijuana dispensaries and stores that ...  |  read more...
USD 129
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025
7/27/2016 | published by: Kalorama Information
... major companies. This report provides long-term company sales forecasts based recent market conditions. For each company covered, the report provides: Corporate Summary Total Company Revenue and Total R&D Spending 2011-2015 Break-up of Sales by Region, ...  |  read more...
USD 3,500
Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026
8/11/2016 | published by: Roots Analysis
... the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment options for diabetic patients worldwide. While ...  |  read more...
USD 2,349
Late Stage Drugs (Phase III) in Oncology: Analytical Tool
8/22/2016 | published by: BioSeeker Group AB
... biotech/pharma professionals from a business development, drug development or investment perspective. BioSeeker’s Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering: Target Scouting Early & ...  |  read more...
USD 20,250
Global Contraception Partnering 2010-2016
9/1/2016 | published by: Current Partnering
... Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides ...  |  read more...
USD 1,495
Pancreatic Beta-Cell Protection - Hot Targets & Pipeline Analysis
8/12/2016 | published by: IQ4I Research and Consultancy
... beta-cell protection in both Type-1 diabetes & Type-2 diabetes disease progression. This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and ...  |  read more...
USD 3,600
Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016
9/1/2016 | published by: Current Partnering
... Comprehensive directory of personalized medicine in oncology deals since 2010 Personalized medicine in oncology contract documents Personalized medicine in oncology agreement terms Personalized medicine in oncology agreement structure Top personalized medicine in oncology deals by ...  |  read more...
USD 2,995
Proof-of-Concept (Phase II) Drugs in Oncology: Analytical Tool
8/22/2016 | published by: BioSeeker Group AB
... professionals from a business development, drug development or investment perspective. BioSeeker’s Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering: Target Scouting Early & Late ...  |  read more...
USD 20,250
Global Dental Partnering 2010-2016: Deal trends, players and financials
9/1/2016 | published by: Current Partnering
... and royalty by stage of development Dental partnering agreement structure Dental partnering contract documents Top Dental deals by value Most active Dental dealmakers Most of the deals included within the report occur when a licensee ...  |  read more...
USD 2,995
Global Orphan Diseases Partnering 2010-2016: Deal trends, players and financials
9/1/2016 | published by: Current Partnering
... for headline, upfront and royalty by stage of development Orphan Diseases partnering agreement structure Orphan Diseases partnering contract documents Top Orphan Diseases deals by value Most active Orphan Diseases dealmakers Most of the deals included ...  |  read more...
USD 2,995
Global Migraine Partnering 2010 to 2016
9/1/2016 | published by: Current Partnering
... Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides ...  |  read more...
USD 1,495
Global Sexually Transmitted Diseases Partnering 2010-2016
9/1/2016 | published by: Current Partnering
... Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides ...  |  read more...
USD 1,495
Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026
8/26/2016 | published by: Roots Analysis
... in intraocular pressure (IOP). Acutely elevated IOP, a condition broadly known as ocular hypertension, may either lead to the expulsion of ocular contents through a traumatic opening or result in a number of clinical conditions ...  |  read more...
USD 2,349
Atrial Fibrillation - Pipeline Review, H2 2016
8/10/2016 | published by: Global Markets Direct
... therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of ...  |  read more...
USD 2,000
Genital Herpes - Pipeline Review, H2 2016
8/10/2016 | published by: Global Markets Direct
... therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of ...  |  read more...
USD 2,000
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016
8/10/2016 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The ...  |  read more...
USD 2,000
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline Review, H2 2016
7/27/2016 | published by: Global Markets Direct
... Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC ...  |  read more...
USD 3,500
Indolent Lymphoma - Pipeline Review, H2 2016
8/10/2016 | published by: Global Markets Direct
... therapeutics under development for Indolent Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of ...  |  read more...
USD 2,000
Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016
7/30/2016 | published by: Global Markets Direct
... Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on Maternal Embryonic Leucine Zipper Kinase (Protein ...  |  read more...
USD 3,500
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2016
7/30/2016 | published by: Global Markets Direct
... Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 ...  |  read more...
USD 3,500
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2016
7/30/2016 | published by: Global Markets Direct
... HAMP) - Pipeline Review, H2 2016’, provides in depth analysis on Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted pipeline therapeutics. The report provides comprehensive information on the Hepcidin ...  |  read more...
USD 3,500
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H2 2016
7/30/2016 | published by: Global Markets Direct
... Pipeline Review, H2 2016’, provides in depth analysis on Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information on the Histone Deacetylase 8 (Histone ...  |  read more...
USD 3,500
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2016
7/20/2016 | published by: Global Markets Direct
... Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Tyrosine Protein Kinase Receptor ...  |  read more...
USD 3,500
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016
7/20/2016 | published by: Global Markets Direct
... H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or ...  |  read more...
USD 3,500
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H1 2016
6/30/2016 | published by: Global Markets Direct
... H1 2016 Summary Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or ...  |  read more...
USD 3,500
< prev 1    3  4  5  6  7  8  9  10